Gastrinoma

Bailliere's Clinical Gastroenterology

Volumn 10, Issue 4, 1996, Pages 603-643

  Jensen, Robert T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROZOTOCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON; LANSOPRAZOLE; OMEPRAZOLE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GASTRINOMA; HYPERGASTRINEMIA; LIVER METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; REVIEW; STOMACH ACID; ZOLLINGER ELLISON SYNDROME; CANCER INVASION; CANCER STAGING; FEMALE; HUMAN; MALE; PANCREAS; PANCREAS TUMOR; PATHOLOGY;

FEMALE; GASTRINOMA; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS;

EID: 0030323325     PISSN: 09503528     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3528(96)90016-0     Document Type: Article

References (207)

1. Anthony L, Johnson D, Hande K et al (1993) Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncologica 32: 217-223.
2. Anthuber M, Jauch KW, Briegel J et al (1996) Results of liver transplantation for gastroentero-pancreatic tumor metastases. World Journal of Surgery 20: 73-76.
3. Arcenas AG, Ajani JA, Carrasco CH et al (1995) Vascular occlusive therapy of pancreatic endocrine tumors metastatic to the liver. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 439-450. Basel: S. Karger.
4. Arnold A (1994) Molecular mechanisms of parathyroid neoplasia. Endocrinology and Metabolism Clinics of North America 23: 93-107.
5. Arnold R & Frank M (1995) Systemic chemotherapy for endocrine tumors of the pancreas: recent advances. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 431-438. Basel: S. Karger.
6. Arnold R, Benning R, Neuhaus C et al (1992) Gastroenteropancreatic endocrine tumors: effect of Sandostatin on tumor growth. The German Sandostatin Study Group. Metabolism 41 (9 supplement 2): 116-118.
7. Arnold R, Neuhaus C, Benning R et al (1993). Somatostatin analog Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World Journal of Surgery 17: 511-519.
8. Arnold R, Frank M & Kajdan U (1994) Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion 55: 107-113.
9. Arnold R, Trautmann ME, Creutzfeldt W et al (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38: 430-438.
10. Azoulay D & Bismuth H (1995) Role of liver surgery and transplantation in patients with hepatic metastases from pancreatic endocrine tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 461-476. Basel: S. Karger.
11. Bale AE (1994) Molecular mechanisms of neoplasia in multiple endocrine neoplasia type 1-related and sporadic tumors of the pancreatic islet cells. Endocrinology and Metabolism Clinics of North America 23: 109-115.
12. Bardram L (1990a) Progastrin in serum from Zollinger-Ellison patients. An indicator of malignancy? Gastroenterology 98: 1420-1426.
13. Bardram L (1990b) Progastrin in pancreas and the Zollinger-Ellison syndrome. Scandinavian Journal of Gastroenterology 25: 1185-1195.
14. Benya RV, Metz DC, Venzon DJ et al (1994) Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. American Journal of Medicine 97: 436-444.
15. Bonfils S, Ruszniewski P, Haffar S & Laucournet H (1986) Chemotherapy of hepatic metastases (HM) in Zollinger-Ellison syndrome (ZES). Report of a multicentric analysis. Digestive Diseases and Sciences 31: 510S (abstract).
16. Bonfils S, Jensen RT, Malagelada J & Stadil F (1989) Zollinger-Ellison syndrome management: a protocol for strategy. Gastroenterology International 2: 9-15.
17. Broder LE & Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Annals of Internal Medicine 79: 108-118.
18. Bruns C, Weckbecker G, Raulf F et al (1994) Molecular pharmacology of somatostatin-receptor subtypes. Annals of the New York Academy of Sciences 733: 138-146.
19. Bukowski RM, Tangen C, Lee R et al (1992) Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. Journal of Clinical Oncology 10: 1914-1918.
20. Cadiot G, Laurent-Puig P, Thuille B et al (1993) Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 105: 579-582.
21. Carney JA, Go VLW, Fairbanks JF et al (1983) The syndrome of gastric argyophil carcinoid tumors and nonantral gastric atropy. Annals of Internal Medicine 99: 761-766.
22. Carrasco CH, Chuang VP & Wallace S (1983) Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 149(1): 79-83.
23. Carty SE, Jensen RT & Norton JA (1992) Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112: 1024-1031.
24. Chaudhry A & Oberg K (1995) Expression of growth factor peptides and adhesion molecules in endocrine pancreatic tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23, pp 132-146. Basel: S. Karger.
25. Chaudhry A, Gobi A, Eriksson B et al (1994) Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Research 54: 981-986.
26. Chemer JA, Doppman JL, Norton JA et al (1986) Selective venous sampling for gastrin to localize gastrinomas. A prospective study. Annals of Internal Medicine 105: 841-847.
27. Chiang HC, O'Dorisio TM, Huang SC et al (1990) Multiple hormone elevations in patients with Zollinger-Ellison syndrome: prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology 99: 1565-1575.
28. Collen MJ, Howard JM, McArthur KE et al (1984) Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. Annals of Internal Medicine 100: 52-58.
29. Corleto VD, Scopinaro F, Angeletti S et al (1996) Somatostatin receptor localization of pancreatic endocrine tumors. World Journal of Surgery 20: 241-244.
30. Crean GP, Marshall MW & Ramsey RD (1969) Parietal cell hyperplasia induced by the administration of pentagastrin (ICI-50,123) to rats. Gastroenterology 57: 147-155.
31. Creutzfeldt W (1988) The achlorhydria-carcinoid sequence: role of gastrin. Digestion 39: 61-79.
32. Creutzfeldt W, Arnold R, Creutzfeldt C & Track NS (1975) Pathomorphologic, biochemical and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome). Human Pathology 6: 47-76.
33. D'Adda T, Bertele A, Pilato FP & Bordi C (1989) Quantitative electron microscopy of endocrine cells in oxyntic mucosa of normal human stomach. Cell and Tissue Research 255: 41-48.
34. D'Adda T, Corleto V, Pilato FP et al (1990) Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings. Gastroenterology 99: 17-26.
35. de Kerviler E, Cadiot G, Lebtahi R et al (1994) Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. European Journal of Nuclear Medicine 21: 1191-1197.
36. Debelenko LV, Emmert-Buck MR, Zhuang Z et al (1996) Frequent allelic deletions of MEN-I. American Journal of Clinical Pathology (abstract) (in press).
37. del Valle J, Sugano K & Yamada T (1987) Progastrin and its glycine-extended posttranslational processing intermediates in human gastrointestinal tissues. Gastroenterology 92: 1908-1912.
38. Delcore R & Friesen SR (1994) The place for curative surgical procedures in the treatment of sporadic and familial Zollinger-Ellison syndrome. Current Opinion in General Surgery 69-76.
39. Deveney CW, Deveney KS, Stark D et al (1983) Resection of gastrinomas. Annals of Surgery 198: 546-553.
40. Dockray GJ & Walsh JH (1975) Amino terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients. Gastroenterology 68: 222-230.
41. Dousset B, Houssin D, Soubrane O et al (1995) Metastatic endocrine tumors: is there a place for liver transplantation? Liver Transplant Surgery 1: 111-117.
42. Ekman L, Hansson E, Havu N et al (1985) Toxicological studies on omeprazole. Scandinavian Journal of Gastroenterology 20 (supplement 108): 53-69.
43. el-Omar EM, Penman ID, Ardill JE et al (1995) Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 109: 681-691.
44. Ellison EH & Wilson SD (1964) The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Annals of Surgery 160: 512-530.
45. Eriksson B (1995) Tumor markers for pancreatic endocrine tumors, including chromogranins, HCG-alpha and HCG-beta. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 121-131. Basel: S. Karger.
46. Eriksson B & Oberg K (1995) Interferon therapy of malignant endocrine pancreatic tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 451-460. Basel: S. Karger.
47. Eriksson B, Oberg K, Aim G et al (1986) Treatment of malignant endocrine pancreatic tumors with human leucocyte interferon. Lancet 2: 1307-1309.
48. Eubanks PJ, Sawicki MP, Samara GJ et al (1994) Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. American Journal of Surgery 167: 180-185.
49. Evers BM, Rady PL, Sandoval K et al (1994) Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Annals of Surgery 219: 596-604.
50. Fishbeyn VA, Norton JA, Benya RV et al (1993) Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Annals of Internal Medicine 119: 199-206.
51. Fraker DL & Jensen RT (in press) Pancreatic endocrine tumors. In DeVita VT, Hellman S & Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. 5th edn. pp 1678-1704. Philadelphia: J.B. Lippincott.
52. Fraker DL, Norton JA, Alexander HR et al (1994) Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Annals of Surgery 220: 320-330.
53. Frucht H, Doppman JL, Norton JA et al (1989a) Gastrinomas: comparison of MR imaging with CT, angiography and US. Radiology 171: 713-717.
54. Frucht H, Howard JM, Slaff JI et al (1989b) Secretin and calcium provocative tests in the Zollinger-Ellison syndrome: a prospective study. Annals of Internal Medicine 111: 713-722.
55. Frucht H, Norton JA, London JF et al (1990) Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology 99: 1622-1627.
56. Frucht H, Maton PN & Jensen RT (1991) Use of omeprazole in patients with the Zollinger-Ellison syndrome. Digestive Diseases and Sciences 36: 394-404.
57. Gibril F, Doppman JL, Chang R et al (1996b) Metastatic gastrinomas: localization with selective arterial injection of secretin. Radiology 198: 77-84.
58. Gibril F, Reynolds JC, Doppman JL et al (1996a) Somatostatin receptor scintigraphy: a prospective study of its sensitivity compared to other imaging modalities in detecting primary and metastatic gastrinomas. Annals of Internal Medicine 125: 26-34.
59. Gregory RA, Tracy HJ, French JM & Sircus W (1960) Extraction of a gastrin-like substance from a pancreatic tumor in a case of Zollinger-Ellison syndrome. Lancet 1: 1045-1048.
60. Gregory RA, Grossman MI, Tracy HJ & Bentley PH (1967) Nature of the gastric secretagogue in Zollinger-Ellison tumors. Lancet 2: 543-544.
61. Gregory RA, Tracy HJ, Agarwal KL & Grossman MI (1969) Aminoacid constitution of two gastrins isolated from Zollinger-Ellison tumor tissue. Gut 10: 603-608.
62. Hakanson R, Ekelund M & Sundler F (1984) Activation and proliferation of gastric endocrine cells. In Falkmer S, Hakanson R & Sundler F (eds) Evolution and Tumor Pathology of the Neuroendocrine System, pp 371-398. Amsterdam: Elsevier.
63. Havu N (1986) Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35 (supplement 1): 42-55.
64. Helander HF & Bordi C (1995) Morphology of gastric mucosa during prolonged hypergastrinemia. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 372-384. Basel: S. Karger.
65. Hirschowitz BI (1995) Clinical course of nonsurgically treated Zollinger-Ellison syndrome. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, pp 360-371. Basel: S. Karger.
66. Hofmann JW, Fox PS & Wilson SD (1973) Duodenal wall tumors and the Zollinger-Ellison syndrome. Surgical management. Archives of Surgery 107: 334-339.
67. Howard TJ, Sawicki M, Lewin KJ et al (1995) Pancreatic polypeptide immunoreactivity in sporadic gastrinoma: relationship to intraabdominal location. Pancreas 11: 350-356.
68. Imamura M & Takahashi K (1993) Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World Journal of Surgery 17: 433-438.
69. Imamura M, Takahashi K, Adachi H et al (1987) Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Annals of Surgery 205: 230-239.
70. Jais P & Mignon M (1995) Normal serum gastrin concentration in gastrinoma. Lancet 346: 1421-1422 (letter).
71. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG et al (1990) Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99: 621-628.
72. Jensen RT (1984) Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome. Digestive Diseases and Sciences 29: 363-366.
73. Jensen RT (1993) Gastrinoma as a model for prolonged hypergastrinemia in man. In Walsh JH (ed.) Gastrin, pp 373-393. New York: Raven Press.
74. Jensen RT (1994) Zollinger-Ellison syndrome: past, present, and future controversies. Yale Journal of Biology and Medicine 67: 195-214.
75. Jensen RT (1995) Pancreatic endocrine tumors. Current Opinion in Gastroenterology 11: 423-429.
76. Jensen RT (1996) Should the 1996 citation for Zollinger-Ellison syndrome read: 'Acid-reducing surgery in, aggressive resections out?'. American Journal of Gastroenterology 91: 1067-1070.
77. Jensen RT & Dayal Y (1992) Long-term clinical effects of hypergastrinemia in man. Regulatory Peptides Letter 4: 31-39.
78. Jensen RT & Fraker DL (1994) Zollinger-Ellison syndrome: advances in treatment of the gastric hypersecretion and the gastrinoma. Journal of the American Medical Association 271: 1-7.
79. Jensen RT & Gardner JD (1993) Gastrinoma. In Go VLW, DiMagno EP, Gardner JD et al (eds) The Pancreas: Biology, Pathobiology and Disease, 2nd edn. pp 931-978. New York: Raven Press.
80. Jensen RT & Maton PN (1992) Zollinger-Ellison syndrome. In Gustavsson S, Kumar D & Graham DY (eds) The Stomach, pp 341-374. London: Churchill Livingstone.
81. Jensen RT & Norton JA (1995) Endocrine tumors of the pancreas. In Yamada T, Alpers BH, Owyang C et al (eds) Textbook of Gastroenterology, 2nd edn. pp 2131-2166. Philadelphia, PA: J.B. Lippincott.
82. Jensen RT, Collen MJ, Allende HD et al (1983a) Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. New England Journal of Medicine 308: 883-887.
83. Jensen RT, Gardner JD, Raufman JP et al (1983b) Zollinger-Ellison syndrome: current concepts and management. Annals of Internal Medicine 98: 59-75.
84. Jensen RT, Collen MJ, McArthur KE et al (1984a) Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric acid hypersecretory states. American Journal of Medicine 77(5B): 90-105.
85. Jensen RT, Collen MJ, McArthur KE et al (1984b) Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. In Misiewicz JJ & Wood JR (eds) Ranitidine: Therapeutic Advances, pp 168-198. Amsterdam: Excerpta Medica.
86. Kloppel G, Schroder S & Heitz PU (1995) Histopathology and immunopathology of pancreatic endocrine tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 99-120. Basel: S. Karger.
87. Kochman ML, DelValle J, Dickinson CJ & Boland CR (1992) Post-translational processing of gastrin in neoplastic human colonic tissues. Biochemical and Biophysical Research Communications 189: 1165-1169.
88. Krenning SWJ, Bakker WH, Breeman WAP et al (1989) Localization of endocrine related tumors with radiolabelled analogue of somatostatin Lancet i: 242-245.
89. 3]-octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20: 716-731.
90. Krenning EP, Kwekkeboom DJ, Oei HY et al (1994) Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. Annals of the New York Academy of Sciences 733: 416-424.
91. Kvols LK, Buck M, Moertel CG et al (1987) Treatment of metastatic islet cell tumors with somatostatin analogue. Annals of Internal Medicine 107: 162-168.
92. Lamberts R, Creutzfeldt W, Struber HG et al (1993) Long-term omeprazole therapy in peptic ulcer disease, gastrin, endocrine cell growth, and gastritis. Gastroenterology 104: 1356-1370.
93. Lamberts SWJ, van der Lely AJ, de Herder WW & Hofland LJ (1996) Octreotide. New England Journal of Medicine 334: 246-254.
94. 2-receptor antagonists. New England Journal of Medicine 310: 758-761.
95. Landis CA, Masters SB, Spada A et al (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692-696.
96. Larsson LI, Rehfeld JF & Goltermann N (1977) Gastrin in the human fetus: distribution and molecular forms of gastrin in the antro-pyloric gland area, duodenum and pancreas. Scandinavian Journal of Gastroenterology 12: 869-872.
97. Lehy T, Mignon M, Cadiot G et al (1989) Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 96: 1029-1040.
98. Lehy T, Cadiot G, Mignon M et al (1992) Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33: 1275-1279.
99. London J, Frucht H, Doppman JL et al (1989) Zollinger-Ellison syndrome in the acute care setting. Journal of Intensive Care Medicine 4: 272-283.
100. Lyons J, Landis CA, Harsh G et al (1990) Two G protein oncogenes in human endocrine tumors. Science 249: 655-659.
101. MacFarlane MP, Fraker DL, Alexander HR et al (1995) A prospective study of surgical resection of duodenal and pancreatic gastrinomas. Surgery 118: 973-980.
102. Malagelada J, Edis AJ, Adson MA et al (1983) Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84: 1524-1532.
103. Maton PN (1989) The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterology Clinics of North America 18: 897-922.
104. Maton PN & Dayal Y (1991) Clinical implications of hypergastrinemia. In Zakim D & Dannenberg AJ (eds) Peptic Ulcer Disease and Other Acid-Related Disorders, pp 213-246. Armonk, NY: Academic Research Associates.
105. Maton PN, Frucht H, Vinayek R et al (1988) Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study. Gastroenterology 94: 294-299.
106. Maton PN, Gardner JD & Jensen RT (1986) Cushing's syndrome in patients with Zollinger-Ellison syndrome. New England Journal of Medicine 315: 1-5.
107. Maton PN, Gardner JD & Jensen RT (1989a) Use of the long-acting somatostatin analog, SMS 201-995 in patients with pancreatic islet cell tumors. Digestive Diseases and Sciences 34: 28S-39S.
108. Maton PN, Mackem SM, Norton J A et al (1989b) Ovarian carcinoma as a cause of Zollinger-Ellison syndrome. Natural history, secretory products and response to provocative tests. Gastroenterology 97: 468-471.
109. Maton PN, Lack EE, Collen MJ et al (1990) The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 99: 943-950.
110. McArthur KE, Richardson CT, Barnett CC et al (1996) Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. American Journal of Gastroenterology 91: 1104-1011.
111. McCarthy DM (1978) Report on the United States experience with cimetidine in Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology 74: 453-458.
112. McCarthy DM (1980) The place of surgery in the Zollinger-Ellison syndrome. New England Journal of Medicine 302: 1344-1347.
113. 2-histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy. Annals of Internal Medicine 87: 668-675.
114. McEntee GP, Nagorney DM, Kvols LK et al (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108: 1091-1096.
115. McGuigan JE & Trudeau WL (1968) Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. New England Journal of Medicine 278: 1308-1313.
116. Metz DC & Jensen RT (1995) Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 240-257. Basel: S. Karger.
117. Metz DC, Kuchnio M, Fraker DL et al (1993a) Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology 105: 799-813.
118. Metz DC, Pisegna JR, Fishbeyn VA et al (1993c) Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World Journal of Surgery 17: 468-480.
119. Metz DC, Pisegna JR, Ringham GL et al (1993d) Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Digestive Diseases and Sciences 38: 245-256.
120. Metz DC, Strader DB, Orbuch M et al (1993d) Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Alimentary Pharmacology and Therapeutics 7: 597-610.
121. Metz DC, Jensen RT, Bale AE et al (1994) Multiple endocrine neoplasia type 1: clinical features and management. In Bilezekian JP, Levine MA & Marcus R (eds) The Parathyroids, pp 591-646. New York: Raven Press.
122. Metz DC, Weber HC, Orbuch M et al (1995) Helicobacter pylori infection: a reversible cause of hypergastrinemia and hyperchlorhydria which can mimic Zollinger-Ellison syndrome. Digestive Diseases and Sciences 40: 153-159.
123. Mignon M, Ruszniewski P, Haffar S et al (1986) Current approach to the management of tumoral process in patients with gastrinoma. World Journal of Surgery 10: 703-710.
124. Mignon M, Cadiot G, Rigaud D et al (1995a) Management of islet cell tumors in patients with multiple endocrine neoplasia type 1. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23, pp 342-359. Basel: S. Karger.
125. Mignon M, Jais P, Cadiot G et al (1995b) Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23, pp 223-239. Basel: S. Karger.
126. Miller LS, Vinayek R, Frucht H et al (1990) Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 98: 341-346.
127. Miller LS, Doppman J, Maton PN et al (1991) Zollinger-Ellison syndrome. Advances in diagnosis and treatment. Handbook of Experimental Pharmacology 99: 349-400.
128. Miller DL, Doppman JL, Metz DC et al (1992) Zollinger-Ellison syndrome: technique, results and complications of portal venous sampling. Radiology 182: 235-241.
129. Moertel CG, Hanley JA & Johnson LA (1980) Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 303: 1189-1194.
130. Moertel CG, Kvols LK, O'Connell MJ & Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232.
131. Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozotocin-doxorubicin, streptozotocin-flourouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. New England Journal of Medicine 326: 519-523.
132. Moertel CG, Johnson CM, McKusick MA et al (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Annals of Internal Medicine 120: 302-309.
133. Mukai K, Grotting JC, Greider MH & Rosai J (1982) Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. American Journal of Surgical Pathology 6: 387-399.
134. Nagorney DM & Que FG (1995) Cytoreductive hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 416-430. Basel: S. Karger.
135. Neuburger P, Lewin M, Recherche CD & Bonfils S (1972) Parietal and chief cell population in four cases of the Zollinger-Ellison syndrome. Gastroenterology 63: 937-942.
136. Norton JA (1994) Advances in the management of Zollinger-Ellison syndrome. Advances in Surgery 27: 129-159.
137. Norton JA (1995) Surgical treatment of islet cell tumors with special emphasis on operative ultrasound. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 309-332. Basel: S. Karger.
138. Norton JA & Jensen RT (1991) Unresolved surgical issues in the management of patients with the Zollinger-Ellison syndrome. World Journal of Surgery 15: 151-159.
139. Norton JA, Doppman JL, Collen MJ et al (1986a) Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Annals of Surgery 204: 468-479.
140. Norton JA, Sugarbaker PH, Doppman JL et al (1986b) Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Annals of Surgery 203: 352-359.
141. Norton JA, Cornelius MJ, Doppmann JL et al (1987) Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome and multiple endocrine neoplasia type I: a prospective study. Surgery 102: 958-966.
142. Norton JA, Cromack DT, Shawker TH et al (1988) Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation. Annals of Surgery 207: 160-168.
143. Norton JA, Doppman JL & Jensen RT (1992) Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Annals of Surgery 215: 8-18.
144. Norton JA, Levin B & Jensen RT (1993) Cancer of the endocrine system. In DeVita VT Jr, Hellman S & Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 4th edn. pp 1333-1435. Philadelphia PA: J.B. Lippincott.
145. Oberg K (1993) The use of chemotherapy in the management of neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 22: 941-952.
146. Oberg K (1994) Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Annals of the New York Academy of Sciences 733: 46-55.
147. Oberhelman HA Jr, Nelsen TS, Johnson AN & Dragstedt LR (1961) Ulcerogenic tumors of the duodenum. Annals of Surgery 153: 214-227.
148. Orbuch M, Doppman JL, Strader DB et al (1995) Imaging for pancreatic endocrine tumor localization: recent advances. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 268-281. Basel: S. Karger.
149. Perry LJ, Stuart K, Stokes KR & Clouse ME (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116: 1111-1117.
150. Pipeleers-Marichal M, Somers G, Willems G et al (1990) Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome. New England Journal of Medicine 322: 723-727.
151. Pisegna JR, Norton JA, Slimak GG et al (1992) Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 102: 767-778.
152. Pisegna JR, Doppman JL, Norton JA et al (1993a) Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Digestive Diseases and Sciences 38: 1318-1328.
153. Pisegna JR, Slimak GG, Doppman JL et al (1993b) An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 105: 1179-1183.
154. Polacek MA & Ellison EH (1966) Parietal cell mass and gastric acid secretion in the Zollinger-Ellison syndrome. Surgery 60: 606-614.
155. Que FG, Nagomey DM, Batts KP et al (1995) Hepatic resection for metastatic neuroendocrine carcinomas. American Journal of Surgery 169: 36-43.
156. Raufman JP, Collins SM, Pandol SJ et al (1983) Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 84: 108-113.
157. Rehfeld JF & Bardram L (1995) Prohormone processing and pancreatic endocrine tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 84-98. Basel: S. Karger.
158. Rehfeld JF & van Solinge WW (1994) The tumor biology of gastrin and cholecystokinin. Advances in Cancer Research 63: 295-347.
159. Reubi JC, Laissue J, Waser B et al (1994) Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Annals of the New York Academy of Sciences 733: 122-137.
160. 2-receptor antagonists. A prospective study. Gastroenterology 89: 357-367.
161. Routley D, Ramage JK, McPeake J et al (1995) Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transplant Surgery 1: 118-121.
162. Ruszniewski P, Hochlaf S, Rougier P & Mignon M (1991) Intravenous chemotherapy with streptozotocin and 5-fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients. Gastroenterology and Clinical Biology 15: 393-398.
163. Ruszniewski P, Podevin P, Cadiot G et al (1993a) Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 8: 295-304.
164. Ruszniewski P, Rougier P, Roche A et al (1993b) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71: 2624-2630.
165. Ruszniewski P, Amouyal P, Amouyal G et al (1995a) Localization of gastrinomas by endoscopic ultra-sonography in patients with Zollinger-Ellison syndrome. Surgery 117: 629-635.
166. Ruszniewski P, Amouyal P, Amouyal G et al (1995b) Endocrine tumors of the pancreatic area: localization by endoscopic ultrasonography. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 258-267. Basel: S. Karger.
167. Saeed ZA, Norton JA, Frank WO et al (1989) Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 96: 1393-1402.
168. Saltz L, Trochanowski B, Buckley M et al (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72: 244-248.
169. Sawicki MP, Wan YJ, Johnson CL et al (1992) Loss of heterozygosity on chromosome 11 in sporadic gastrinomas. Human Genetics 89: 445-449.
170. Scarpignato C (1995) Somatostatin analogues in the management of endocrine tumors of the pancreas. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research. vol. 23 pp 385-414. Basel: S. Karger.
171. von Schrenck T, Howard JM, Doppman JL et al (1988) Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 94: 1326-1334.
172. Shepherd JJ, Challis DR, Davies PF et al (1993) Multiple endocrine neoplasm, type 1: gastrinomas, pancreatic neoplasms, microcarcinoids, the
173. Skogseid B & Oberg K (1995) Genetics of multiple endocrine neoplasia type 1. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 60-69. Basel: S. Karger.
174. Solcia E, Capella C, Sessa F et al (1986) Gastric carcinoids and related endocrine growths. Digestion 35 (supplement 1): 3-22.
175. Solcia E, Bordi C, Creutzfeldt W et al (1988) Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41: 185-200.
176. Solcia E, Capella C, Fiocca R et al (1989) The gastroenteropancreatic endocrine system and related tumors. Gastroenterology Clinics of North America 18: 671-693.
177. Solcia E, Capella C, Fiocca R et al (1990) Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. American Journal of Surgical Pathology 14: 503-513.
178. van Solinge WW, Odum L & Rehfeld JF (1993) Ovarian cancers express and process progastrin. Cancer Research 53: 1823-1828.
179. Stadil F (1995) Treatment of gastrinomas with pancreatoduodenectomy. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 333-341. Basel: S. Karger.
180. Stokes KR, Stuart K & Clouse ME (1993) Hepatic arterial chemoembolization for metastatic endocrine tumors. Journal of Vascular Interventional Radiology 4: 341-345.
181. Strader DB, Doppman JL, Orbuch M et al (1995) Functional localization of pancreatic endocrine tumors. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 282-297. Basel: S. Karger.
182. Stremple JF & Meade RC (1968) Production of antibodies to synthetic human gastrin I and radio-immunoassay of gastrin in the serum of patients with the Zollinger-Ellison syndrome. Surgery 64(1): 165-174.
183. Sugg SL, Norton JA, Fraker DL et al (1993) A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Annals of Surgery 218: 138-144.
184. Syversen U, Mignon M, Bonfils S et al (1993) Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncologica 32: 161-165.
185. Thom AK, Norton JA, Axiotis CA & Jensen RT (1991) Location, incidence and malignant potential of duodenal gastrinomas. Surgery 110: 1086-1093.
186. Thom AK, Norton JA, Doppman JL et al (1992) Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 112(6): 1002-1008.
187. Thompson JC, Lewis BG, Wiener I & Townsend CM Jr (1983) The role of surgery in the Zollinger-Ellison syndrome. Annals of Surgery 197(5): 594-607.
188. Thompson NW, Czako PF, Fritts LL et al (1994) Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery 116: 1131-1138.
189. 111In-pentatreotide. Clinical Endocrinology 38: 501-506.
190. Vessey SJR, Jones PM, Wallis SC et al (1994) Absence of mutations in the Gsα and Gi2α genes in sporadic parathyroid adenomas and insulinomas. Clinical Science 87: 493-497.
191. Vinayek R, Frucht H, London JF et al (1990) Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 99: 10-16.
192. Vinayek R, Amantea MA, Maton PN et al (1991) Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology 101: 138-147.
193. Vinayek R, Hahne WF, Euler AR et al (1993) Parenteral control of gastric hypersecretion in patients with Zollinger-Ellison syndrome. Digestive Diseases and Sciences 38: 1857-1865.
194. Walsh JH (1994) Gastrin. In Walsh JH & Dockray GJ (eds) Gut Peptides, pp 75-121. New York: Raven Press.
195. Waxman I, Gardner JD, Jensen RT & Maton PN (1991) Peptic ulcer perforation as the presentation of Zollinger-Ellison syndrome. Digestive Diseases and Sciences 16: 19-24.
196. Weber HC & Jensen RT (1996) Pancreatic endocrine tumors and carcinoid tumors: recent insights from genetic and molecular biologic studies. In Dervenis CG (ed.) Advances in Pancreatic Diseases; Molecular Biology, Diagnosis and Treatment pp 55-75. Stuttgart: Georg Thiem Verlag.
197. Weber HC, Venzon DJ, Lin JT et al (1995b) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108: 1637-1649.
198. Weber HC, Orbuch M & Jensen RT (1995a) Diagnosis and management of Zollinger-Ellison syndrome. In Jensen RT (ed.) Pancreatic Endocrine Tumors. Seminars in Gastrointestinal Diseases, pp 79-89. Duluth, MN: W.B. Saunders.
199. Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. American Journal of Medicine 16: 363-371.
200. Wilder RM, Allan FN, Power WH & Robertson HE (1927) Carcinoma of the islands of the pancreas: hyperinsulinism and hypoglycemia. Journal of the American Medical Association 89: 348-355.
201. Willems G (1995) Trophic action of gastrin on specific target cells in the gut. In Mignon M & Jensen RT (eds) Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research, vol. 23 pp 30-44. Basel: S. Karger.
202. Wolfe MM & Jensen RT (1987) Zollinger-Ellison syndrome: current concepts in diagnosis and management. New England Journal of Medicine 317: 1200-1209.
203. Yashiro T, Fulton N, Hara H et al (1993) Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114: 758-764.
204. Zeiger MA & Norton JA (1993) Gs alpha-identification of a gene highly expressed by insulinoma and other endocrine tumors. Surgery 114: 458-462.
205. Zimmer T, Stolzel U, Bader M et al (1995) Brief report: a duodenal gastrinoma in a patient with diarrhea and normal serum gastrin concentrations. New England Journal of Medicine 333: 634-636.
206. Zollinger RM & Ellison EH (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Annals of Surgery 142: 709-728.
207. Zollinger RM, Ellison EC, Fabri PJ et al (1980) Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five-year appraisal. Annals of Surgery 192: 422-430.